Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2012-04-12 Major Shareholding Noti…
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Ceasing to be a substantial holder 3 pages 29.3KB
Major Shareholding Notification Classification · 100% confidence The document is titled 'Form 605' and references Corporations Law Section 671B, which pertains to notices of ceasing to be a substantial holder. The content details changes in substantial shareholdings, including dates, nature of changes, and securities affected. This matches the definition of a Major Shareholding Notification, which involves notifications of changes in significant share ownership levels. There is no indication that this is an annual report, audit report, or any other type of filing. The document is not a report publication announcement or a certification. Therefore, the appropriate classification is Major Shareholding Notification (MRQ).
2012-04-12 English
Becoming a substantial holder 8 pages 234.8KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 603 Notice of Initial Substantial Holder filed under Corporations Law Section 671B. It details the substantial shareholding of UBS AG and related entities in Pharmaxis Limited, including voting power, relevant interests, associates, and acquisition details. This type of filing is a notification of a major shareholding change, specifically the initial substantial holder notice. It is not a financial report, earnings release, or management report. It is a regulatory disclosure about share ownership thresholds being crossed. Therefore, the appropriate classification is Major Shareholding Notification (MRQ). The document length and content confirm it is not a brief announcement or a report publication notice, but a substantive notification filing.
2012-04-10 English
Pharmaxis Announces Agreement for EU Supply of Bronchitol 2 pages 83.3KB
Capital/Financing Update Classification · 85% confidence The document is a media release announcing a logistics and distribution agreement for the supply of a pharmaceutical product (Bronchitol) in Europe. It contains no financial data, no regulatory filing references, no voting results, no management changes, no earnings or financial report content. It is a corporate announcement about a commercial agreement and product launch preparation. The document length is 4502 characters, which is relatively short and typical for a press release. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. The best fitting category is Capital/Financing Update (CAP) because it relates to a commercial supply agreement impacting the company's capital or business operations, although it is not a direct financing event, it is the closest relevant category for a business agreement announcement. Confidence is high given the clear nature of the announcement and absence of other category indicators.
2012-03-28 English
European Regulatiry Update on Bronchitol 2 pages 80.5KB
Regulatory Filings Classification · 95% confidence The document is a media release dated 16 March 2012 from Pharmaxis Ltd providing an update on the regulatory status of their product Bronchitol in Europe. It discusses the nearing completion of the European Commission's Marketing Authorisation process, plans for commercial launch, and ongoing regulatory filings such as the New Drug Application (NDA) with the US FDA. The content is focused on regulatory progress and commercial plans rather than financial results, management changes, or detailed financial data. It is a public announcement about regulatory and commercial developments rather than a formal report or filing. Therefore, it fits best into the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2012-03-15 English
Bronchitol to be Reimbursed in Australia 2 pages 90.0KB
Regulatory Filings Classification · 95% confidence The document is a media release announcing that Pharmaxis' drug Bronchitol has been recommended for reimbursement listing on the Australian Pharmaceutical Benefits Scheme (PBS). It discusses regulatory decisions, clinical trial background, and company information. There are no financial statements, earnings data, or detailed financial analysis. The document is a public announcement of a regulatory and commercial milestone rather than a financial report or detailed investor presentation. It does not fit categories like Annual Report, Earnings Release, or Investor Presentation. It is a regulatory announcement about reimbursement status and market access. Therefore, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance-related news that do not fit other specific categories.
2012-03-13 English
Change of Director`s Interest Notice 2 pages 73.9KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rules and the Corporations Act. It details changes in securities holdings by a company director, including the number of shares disposed and held before and after the change. This type of document is a report of personal share transactions by company directors and executives, commonly known as insider trades. It does not contain financial statements, earnings data, or management discussion, nor is it an announcement of a report. The document length is 3650 characters, which is consistent with a detailed insider trading notice. Therefore, the appropriate classification is Director's Dealing (DIRS).
2012-02-26 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.